from Jules: essentially in treatment-naive GT1 we have 99.7% SVR-cure rates with 1 relapse or viral failure in each of the Mavyret or Epclusa studies of hundreds of patients with either 8 or 12 weeks therapy. Mavyret approved for 8 weeks in GT1 treatment-naives. Vosevi (SOF/Velapasvir/Voxilaprevir) is the approved regimen for previously DAA treated failures. As stated in FDA PI - Mavyret is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both - study results below. Visevi FDA PI says - is indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have (1, 2.2, 14): • genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. • genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. SOF+G/P has been studied, reported results below & effective. Treating former or current IV drug users is no longer contraindicated, as stated by AASLD/IDSA guidelines and it is commonly said now by leading HCV treaters that IVDUs can & should be treated, of course support is needed for these patients regarding adherence & reinfection, reported studies below show good SVR-cure rates for these patients: Simplify, Prevail, C-Edge Co-Star studies.HCV/HIV coinfected respond equally well to HCV therapy. Studies for reatment for HCV patients with kidney disease show excellent results, studies reported below.